159 results
Page 4 of 8
8-K
EX-99.1
ni0ci 8bqq8mp03sdoxw
1 Jul 21
Other Events
6:11am
8-K
EX-99.1
s25psgeyofc
14 Jun 21
Other Events
5:21pm
8-K
EX-99.1
kr2y64evlvgcnpiz
26 May 21
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
10:17am
8-K
6gm e7bzjjcxhf1lu2w
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
io3amlntn1vopkmxjq
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
d1w r1dox9gfeiri3
21 May 21
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
7:28am
8-K
EX-99.1
pr9j z9ybbteawl
18 May 21
Other Events
3:09pm
8-K
EX-99.1
1vpzr fd7zukblst
11 May 21
Other Events
8:34am
8-K
EX-99.2
c31oekiq3
11 May 21
Other Events
8:34am
8-K
EX-99.1
kblrkra0jv9ddyg7ey7
10 May 21
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
4:15pm
8-K/A
EX-99.1
m73hmnqf2 3h5
4 Mar 21
Unaudited Pro Forma Combined Financial Statements
5:16pm
8-K
EX-99.1
h97 eezugd2vxbdr
4 Mar 21
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
7:30am
8-K
EX-99.2
lk42gcf d4e
8 Dec 20
Regulation FD Disclosure
7:40am
8-K
EX-99.1
3ilru2ng8m x85qb2
8 Dec 20
Regulation FD Disclosure
7:40am
8-K/A
EX-99.1
t233tctg
12 Nov 20
Unaudited Pro Forma Combined Financial Statements
4:51pm
8-K
EX-99.2
22bam35ihcyvcnq
10 Nov 20
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:23pm